论文部分内容阅读
保肝药物包括抗氧化制(维生素E、水飞蓟素、还原型谷胱甘肽、甜菜碱等)和其他类型药物(多烯磷脂酰胆碱、熊去氧胆酸、硫普罗宁、甘草酸制剂、己酮可可碱等),是非酒精性脂肪性肝病(NAFLD)防治的合理选择,但尚无特效药。循证医学显示,其可改善临床症状,降低转氨酶,但没有足够证据证实可改善肝脏组织学和延缓疾病进程。保肝药物适用于非酒精性脂肪性肝炎(NASH)患者,一般选用1～2种,应和基础治疗配合,以提高疗效。
The hepatoprotective drugs include antioxidants (vitamin E, silymarin, reduced glutathione, betaine, etc.) and other types of drugs (polyene phosphatidylcholine, ursodeoxycholic acid, tiopronin, glycyrrhizin preparations, Pentoxifylline, etc.), is a reasonable choice for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), but there is no cure. Evidence-based medicine has shown that it can improve clinical symptoms and reduce transaminases, but there is not enough evidence to prove that it can improve liver histology and delay disease progression. Liver-related drugs for non-alcoholic steatohepatitis (NASH) patients, the general selection of 1 or 2, should be combined with the basic treatment to improve the efficacy.